Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments Wages, Salaries and Other

Ratios

Protara Therapeutics (TARA) Preferred Shares Issued (2017 - 2020)

Protara Therapeutics' Preferred Shares Issued history spans 2 years, with the latest figure at -$41.0 million for Q4 2020.

Quarterly Preferred Shares Issued changed N/A to -$41.0 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2020, changed N/A year-over-year, with the annual reading at $25.3 million for FY2020, N/A changed from the prior year.
Preferred Shares Issued came in at -$41.0 million for Q4 2020, down from $41.0 million in the prior quarter.
In the past five years, Preferred Shares Issued ranged from a high of $41.0 million in Q3 2020 to a low of -$41.0 million in Q4 2020.